UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 25

Sortiert nach

The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin

European journal of clinical pharmacology, 2007-07, Vol.63 (7), p.677-686

2007

Volltextzugriff (PDF)

Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial

Annals of internal medicine, 2000-07, Vol.133 (1), p.1

2000

Volltextzugriff (PDF)

FTY720 Pharmacokinetics in Mild to Moderate Hepatic Impairment

Journal of clinical pharmacology, 2005-04, Vol.45 (4), p.446-452

2005

Volltextzugriff (PDF)

Disposition of Caspofungin: Role of Distribution in Determining Pharmacokinetics in Plasma

Antimicrobial Agents and Chemotherapy, 2004-03, Vol.48 (3), p.815-823

2004

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Zolmitriptan in Patients with Mild to Moderate Hypertension: A Double-Blind, Placebo-Controlled Study

Journal of clinical pharmacology, 1998-08, Vol.38 (8), p.685-693

1998

Volltextzugriff (PDF)

Pharmacokinetics of Etoricoxib in Patients with Hepatic Impairment

Journal of clinical pharmacology, 2003-10, Vol.43 (10), p.1136-1148

2003

Volltextzugriff (PDF)

Potential for Interactions between Caspofungin and Nelfinavir or Rifampin

Antimicrobial Agents and Chemotherapy, 2004-11, Vol.48 (11), p.4306-4314

2004

Volltextzugriff (PDF)

Pharmacokinetics of Sirolimus (Rapamycin) in Subjects With Mild to Moderate Hepatic Impairment

Journal of clinical pharmacology, 2005-12, Vol.45 (12), p.1368-1372

2005

Volltextzugriff (PDF)

Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment

Clinical pharmacology and therapeutics, 2001-11, Vol.70 (5), p.425-430

Kovarik, J

2001

Volltextzugriff (PDF)

Pharmacokinetics of Long-Acting Naltrexone in Subjects With Mild to Moderate Hepatic Impairment

Journal of clinical pharmacology, 2005-11, Vol.45 (11), p.1259-1267

2005

Volltextzugriff (PDF)

Pharmacokinetics and safety of Ebastine in patients with impaired hepatic function compared with Healthy volunteers: A phase I open-label study

Clinical pharmacokinetics, 2004-01, Vol.43 (2), p.121-129

2004

Volltextzugriff (PDF)

Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment

Clinical pharmacology and therapeutics, 2001-11, Vol.70 (5), p.425-430

2001

Volltextzugriff (PDF)

Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency

Clinical drug investigation, 2013-09, Vol.33 (9), p.665-673

2013

Volltextzugriff (PDF)

Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers

Pulmonary pharmacology & therapeutics, 2012-04, Vol.25 (2), p.193-199

2012

Volltextzugriff (PDF)

Single- and Multiple-Dose Administration of Caspofungin in Patients With Hepatic Insufficiency: Implications for Safety and Dosing Recommendations

Journal of clinical pharmacology, 2007-08, Vol.47 (8), p.951-961

2007

Volltextzugriff (PDF)

Interactions between Simvastatin and Troglitazone or Pioglitazone in Healthy Subjects

Journal of clinical pharmacology, 2001-05, Vol.41 (5), p.573-581

2001

Volltextzugriff (PDF)

Intravenous conivaptan: effects on the QTc interval and other electrocardiographic parameters in healthy volunteers

Advances in therapy, 2007-03, Vol.24 (2), p.310-318

2007

Volltextzugriff (PDF)

IL-2 and antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity in antigen specific CD4 super(+) T cells

Cellular immunology, 2009-01, Vol.257 (1-2), p.69-79

2009

Volltextzugriff (PDF)

PII-49Lack of clinically significant effect of moderate hepatic insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a dipeptidyl-peptidase-IV (DPP-IV) inhibitor

Clinical pharmacology and therapeutics, 2006-02, Vol.79 (2), p.P49-P49

2006

Volltextzugriff (PDF)

Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers

Biopharmaceutics & drug disposition, 2007-09, Vol.28 (6), p.307-313

2007

Volltextzugriff (PDF)

PII-49

Clinical pharmacology and therapeutics, 2006-02, Vol.79 (2), p.P49-P49

2006

Volltextzugriff (PDF)

Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin

Canadian journal of clinical pharmacology, 2009, Vol.16 (1), p.e165

2009

Volltextzugriff (PDF)

Active-site heterogeneity in subunits of horseshoe crab hemocyanin (Limulus polyphemus)

Journal of inorganic biochemistry, 1993-07, Vol.51 (1-2), p.208-208

1993

Volltextzugriff (PDF)

An integrated, hospital information system based obstetrical medical record and database

Proceedings - Symposium on Computer Application in Medical Care, 1991, p.598-602

1991

Volltextzugriff (PDF)

Teaching about the Religions of the World: A Course Outline

Social education, 1990-09, Vol.54 (5), p.300

1990

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(15)

Publikationsform

Artikel
(24)
magazinearticle
(1)

Sprache

Englisch
(25)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin

Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial

FTY720 Pharmacokinetics in Mild to Moderate Hepatic Impairment

Disposition of Caspofungin: Role of Distribution in Determining Pharmacokinetics in Plasma

Pharmacokinetics and Pharmacodynamics of Zolmitriptan in Patients with Mild to Moderate Hypertension: A Double-Blind, Placebo-Controlled Study

Pharmacokinetics of Etoricoxib in Patients with Hepatic Impairment

Potential for Interactions between Caspofungin and Nelfinavir or Rifampin

Pharmacokinetics of Sirolimus (Rapamycin) in Subjects With Mild to Moderate Hepatic Impairment

Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment

Pharmacokinetics of Long-Acting Naltrexone in Subjects With Mild to Moderate Hepatic Impairment

Pharmacokinetics and safety of Ebastine in patients with impaired hepatic function compared with Healthy volunteers: A phase I open-label study

Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment

Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency

Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers

Single- and Multiple-Dose Administration of Caspofungin in Patients With Hepatic Insufficiency: Implications for Safety and Dosing Recommendations

Interactions between Simvastatin and Troglitazone or Pioglitazone in Healthy Subjects

Intravenous conivaptan: effects on the QTc interval and other electrocardiographic parameters in healthy volunteers

IL-2 and antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity in antigen specific CD4 super(+) T cells

PII-49Lack of clinically significant effect of moderate hepatic insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a dipeptidyl-peptidase-IV (DPP-IV) inhibitor

Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers

PII-49

Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin

Active-site heterogeneity in subunits of horseshoe crab hemocyanin (Limulus polyphemus)

An integrated, hospital information system based obstetrical medical record and database

Teaching about the Religions of the World: A Course Outline

Suchergebnisse filtern